Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSEAMERICAN:CVM NASDAQ:OGI NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$10.03+0.3%$8.11$56.35▼$105.00$290.72M0.9512,438 shs329,581 shsCVMCel-Sci$9.19-0.3%$9.74$1.98▼$32.70$63.19M0.52331,118 shs52,230 shsOGIOrganigram Global$1.70-1.5%$1.75$0.85▼$2.08$227.91M1.48741,040 shs472,017 shsPBYIPuma Biotechnology$5.23+1.1%$5.01$2.32▼$6.07$263.19M1.39484,970 shs348,929 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+6.72%+10.01%+34.77%+11.36%-87.79%CVMCel-Sci+0.77%-6.69%+6.23%+46.42%-65.89%OGIOrganigram Global-5.49%-9.47%-4.44%+10.97%-2.27%PBYIPuma Biotechnology-5.14%-2.64%+16.97%+49.86%+83.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$10.03+0.3%$8.11$56.35▼$105.00$290.72M0.9512,438 shs329,581 shsCVMCel-Sci$9.19-0.3%$9.74$1.98▼$32.70$63.19M0.52331,118 shs52,230 shsOGIOrganigram Global$1.70-1.5%$1.75$0.85▼$2.08$227.91M1.48741,040 shs472,017 shsPBYIPuma Biotechnology$5.23+1.1%$5.01$2.32▼$6.07$263.19M1.39484,970 shs348,929 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+6.72%+10.01%+34.77%+11.36%-87.79%CVMCel-Sci+0.77%-6.69%+6.23%+46.42%-65.89%OGIOrganigram Global-5.49%-9.47%-4.44%+10.97%-2.27%PBYIPuma Biotechnology-5.14%-2.64%+16.97%+49.86%+83.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACVMCel-Sci 0.00N/AN/AN/AOGIOrganigram Global 1.00SellN/AN/APBYIPuma Biotechnology 3.00Buy$7.0036.93% UpsideCurrent Analyst Ratings BreakdownLatest CVM, AVTE, PBYI, and OGI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025OGIOrganigram GlobalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025PBYIPuma BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)9/27/2025OGIOrganigram GlobalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025PBYIPuma BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACVMCel-SciN/AN/AN/AN/A$6.06 per shareN/AOGIOrganigram Global$223.82M1.02N/AN/A$2.07 per share0.82PBYIPuma Biotechnology$238.06M1.08$0.80 per share6.40$1.88 per share2.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)CVMCel-Sci-$26.92M-$9.77N/AN/AN/AN/A-259.38%-107.21%N/AOGIOrganigram Global-$33.39M$0.0534.01N/AN/A2.86%-8.19%-5.79%12/17/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.985.2513.45N/A20.38%53.15%23.51%11/6/2025 (Estimated)Latest CVM, AVTE, PBYI, and OGI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025PBYIPuma Biotechnology$0.09N/AN/AN/AN/AN/A8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACVMCel-SciN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CVMCel-Sci0.890.470.37OGIOrganigram GlobalN/A2.591.42PBYIPuma Biotechnology0.101.731.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACVMCel-Sci12.08%OGIOrganigram Global34.63%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CVMCel-Sci14.06%OGIOrganigram Global0.09%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCVMCel-Sci436.88 million5.91 millionOptionableOGIOrganigram Global860134.46 million134.34 millionOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionableCVM, AVTE, PBYI, and OGI HeadlinesRecent News About These CompaniesRitholtz Wealth Management Invests $676,000 in Puma Biotechnology, Inc. $PBYIOctober 19 at 4:22 AM | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average - What's Next?October 16, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Raised to Buy (B-) at Weiss RatingsOctober 10, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Shares Pass Above Two Hundred Day Moving Average - Here's What HappenedOctober 8, 2025 | marketbeat.com3 High-Flying Stocks Under $10 to Buy Hand Over Fist Right NowOctober 7, 2025 | 247wallst.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | businesswire.comStrs Ohio Purchases Shares of 141,900 Puma Biotechnology, Inc. $PBYISeptember 23, 2025 | marketbeat.comKapitalo Investimentos Ltda Takes $241,000 Position in Puma Biotechnology, Inc. $PBYISeptember 22, 2025 | marketbeat.comWhat Do Analysts Think About Puma Biotechnology (PBYI)?September 17, 2025 | insidermonkey.com12 Affordable Biotech Stocks to Invest In NowSeptember 16, 2025 | insidermonkey.comPBYI Surges 30% in 3 Months: How Should You Play the Stock?September 15, 2025 | zacks.comAre Strong Financial Prospects The Force That Is Driving The Momentum In Puma Biotechnology, Inc.'s NASDAQ:PBYI) Stock?September 4, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | businesswire.comPuma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comPuma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowSeptember 1, 2025 | zacks.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 28, 2025 | zacks.comAdditional Considerations Required While Assessing Puma Biotechnology's (NASDAQ:PBYI) Strong EarningsAugust 15, 2025 | finance.yahoo.comPuma Biotechnology Reports Strong Q2 2025 EarningsAugust 13, 2025 | msn.comBarclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PTAugust 12, 2025 | msn.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?August 12, 2025 | zacks.comPuma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?August 12, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVM, AVTE, PBYI, and OGI Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$10.03 +0.03 (+0.30%) As of 10/21/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Cel-Sci NYSEAMERICAN:CVM$9.18 -0.03 (-0.27%) Closing price 03:59 PM EasternExtended Trading$9.18 -0.01 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Organigram Global NASDAQ:OGI$1.70 -0.03 (-1.45%) Closing price 03:59 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Puma Biotechnology NASDAQ:PBYI$5.22 +0.06 (+1.06%) Closing price 03:59 PM EasternExtended Trading$5.23 +0.01 (+0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
